Loading...
Docoh

Biocryst Pharmaceuticals (BCRX)

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States and Japan for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in the European Union and United Kingdom. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing.

Company profile

Ticker
BCRX
Exchange
CEO
Jon Stonehouse
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
JPR Royalty Sub, LLC • BioCryst US Sales Co., LLC • BioCryst UK Limited • BioCryst Ireland Limited • BioCryst Pharma Deutschland GmbH • BioCryst France SAS ...
IRS number
621413174

BCRX stock data

Analyst ratings and price targets

Last 3 months
Current price
Average target
$14.00
Low target
$14.00
High target
$14.00
Barclays
Maintains
Equal-Weight
$14.00
5 Aug 22
Evercore ISI Group
Downgraded
In-Line
$14.00
5 Aug 22

Calendar

5 Aug 22
12 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 272.57M 272.57M 272.57M 272.57M 272.57M 272.57M
Cash burn (monthly) 40.98M (no burn) 19.33M 19.06M 9.25M 13.44M
Cash used (since last report) 59.64M n/a 28.14M 27.74M 13.47M 19.56M
Cash remaining 212.93M n/a 244.43M 244.84M 259.1M 253.01M
Runway (months of cash) 5.2 n/a 12.6 12.8 28.0 18.8

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
7 Jun 22 Steve Aselage Common Stock Grant Acquire A No No 0 12,866 0 46,594
7 Jun 22 Steve Aselage Automatic Stock Option Grant Common Stock Grant Acquire A No No 10.79 30,022 323.94K 30,022
7 Jun 22 Steven K Galson Common Stock Grant Acquire A No No 0 12,866 0 12,866
7 Jun 22 Steven K Galson Automatic Stock Option Grant Common Stock Grant Acquire A No No 10.79 30,022 323.94K 30,022
7 Jun 22 Lee Kenneth B JR Common Stock Grant Acquire A No No 0 12,866 0 37,118
7 Jun 22 Lee Kenneth B JR Automatic Stock Option Grant Common Stock Grant Acquire A No No 10.79 30,022 323.94K 30,022
7 Jun 22 Alan G Levin Common Stock Grant Acquire A No No 0 12,866 0 16,063
7 Jun 22 Alan G Levin Automatic Stock Option Grant Common Stock Grant Acquire A No No 10.79 30,022 323.94K 30,022
7 Jun 22 Abercrombie George B Common Stock Grant Acquire A No No 0 12,866 0 12,866
7 Jun 22 Abercrombie George B Automatic Stock Option Grant Common Stock Grant Acquire A No No 10.79 30,022 323.94K 30,022
68.4% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 232 206 +12.6%
Opened positions 51 40 +27.5%
Closed positions 25 30 -16.7%
Increased positions 65 73 -11.0%
Reduced positions 70 53 +32.1%
13F shares Current Prev Q Change
Total value 2.2B 1.78B +23.7%
Total shares 127.14M 118.14M +7.6%
Total puts 2.38M 2.98M -20.1%
Total calls 3.83M 3.79M +0.9%
Total put/call ratio 0.6 0.8 -20.8%
Largest owners Shares Value Change
BLK Blackrock 14.1M $229.3M -4.6%
Vanguard 13.21M $214.75M +40.3%
Baker Bros. Advisors 12.71M $206.68M 0.0%
FMR 8.41M $136.82M +116.0%
STT State Street 7.46M $121.34M -9.5%
Pictet Asset Management 5.11M $83.04M +1.0%
Fisher Asset Management 3.99M $64.83M -2.7%
RP Management 3.85M $62.54M 0.0%
Victory Capital Management 3.55M $57.54M +705.3%
Geode Capital Management 3.28M $53.36M +2.0%
Largest transactions Shares Bought/sold Change
FMR 8.41M +4.52M +116.0%
Vanguard 13.21M +3.79M +40.3%
Victory Capital Management 3.55M +3.11M +705.3%
Sarissa Capital Management 1.39M -2.65M -65.6%
Lord, Abbett & Co. 2.32M +2.32M NEW
HealthCor Management 228.45K -2.15M -90.4%
Avoro Capital Advisors 1.88M +1.88M NEW
Sofinnova Investments 0 -1.51M EXIT
Alkeon Capital Management 1.19M +1.19M NEW
Marshall Wace 1.09M +1.09M NEW

Financial report summary

?
Risks
  • Our business, operations, clinical development or commercialization plans and timelines, and access to capital could be adversely affected by the effects of the ongoing COVID-19 pandemic on us or on third parties with whom we conduct business, including without limitation our development partners, manufacturers, CROs, and others, as well as on the regulatory and government agencies with whom we work.
  • We have incurred losses since our inception, expect to continue to incur such losses, and may never be profitable.
  • We may need to raise additional capital in the future. If we are unable to raise capital when needed, we may need to adjust our operations.
  • Our success depends upon our ability to advance our product candidates through the various stages of development, especially through the clinical trial process, and to receive regulatory approval for the commercial sale of our product candidates.
  • If our development collaborations with third parties, such as our development partners, contractors and contract research organizations, fail, the development of our product candidates will be delayed or stopped.
  • If we fail to obtain additional financing or acceptable partnership arrangements as and when needed, we may be unable to complete the development and commercialization of our products and product candidates or continue operations.
  • If we or our partners do not obtain governmental approval for our product candidates or maintain governmental approval for our products, we or our partners will not be able to commercialize and sell these products and potential products, which would significantly harm our business because we will receive no revenue.
  • We focus on rare diseases, which may create additional risks and challenges.
  • The commercial viability of any approved product could be compromised if the product is less effective than expected, causes undesirable side effects that were not previously identified, or fails to achieve market acceptance within the medical community.
  • If we fail to successfully commercialize or establish collaborative relationships to commercialize certain of our products and product candidates, or if any partner terminates or fails to perform its obligations under agreements with us, potential revenues from commercialization of our products and product candidates could be reduced, delayed or eliminated.
  • The results of our partnership with Torii may not meet our current expectations.
  • There can be no assurance that our or our partners’ commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain.
  • We expect to continue expanding our development and regulatory capabilities and implementing sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
  • We depend on third-party vendors in the manufacture and distribution of our products, product candidates and the materials for our products and product candidates. If we cannot rely on existing third-party vendors, we will be required to incur significant costs and potential delays in finding new third-party vendors, which could adversely impact the development and commercialization timeframes for our products and product candidates.
  • We face intense competition, and if we are unable to compete effectively, the demand for our products may be reduced.
  • Developments by others may render our products, product candidates, or technologies obsolete or noncompetitive.
  • We are subject to various laws and regulations related to our products and product candidates, and if we or our partners do not comply with these laws and regulations, we could face substantial penalties.
  • Our employees and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.
  • We are subject to data security and privacy risks, and our actual or perceived failure to comply with regulations and other legal obligations related to privacy and data protection could harm our business.
  • If, because of our use of hazardous materials, we violate any environmental controls or regulations that apply to such materials, we may incur substantial costs and expenses in our remediation efforts.
  • If we fail to adequately protect or enforce our intellectual property rights or secure rights to patents of others, the value of those rights would diminish.
  • We may be involved in legal proceedings to protect or enforce our patents, the patents of our partners or our other intellectual property rights, which could be expensive, time consuming and unsuccessful.
  • We face an inherent risk of liability in the event that the use or misuse of our products or product candidates results in personal injury or death and our product liability insurance coverage may be insufficient.
  • We face risks related to our government-funded programs and are subject to various U.S. Government contract requirements, which may create a disadvantage and additional risks to us.
  • There are risks related to the potential government use or sale of our antivirals.
  • If we fail to reach milestones or to make annual minimum payments or otherwise breach our obligations under our license agreements, our licensors may terminate our agreements with them and seek additional remedies.
  • Royalties and milestone payments, if any, from Shionogi under the Shionogi Agreement are required to be used by Royalty Sub to satisfy its obligations under its PhaRMA Notes, and generally will not be available to us for other purposes unless and until Royalty Sub has repaid in full its obligations under the PhaRMA Notes.
  • Because continuing events of default exist under the PhaRMA Notes, the holders of the PhaRMA Notes may be able to foreclose on the collateral securing the PhaRMA Notes and our equity interest in Royalty Sub. As a result, we may not realize the benefit of future royalty payments, if any, that might otherwise accrue to us following repayment of the PhaRMA Notes and we could otherwise be adversely affected.
  • We have incurred significant indebtedness, which could adversely affect our business. Additionally, our Credit Agreement contains conditions and restrictions that limit our flexibility in operating our business. We may be required to make a prepayment or repay our outstanding indebtedness earlier than we expect if a prepayment event or an event of default occurs, including a material adverse change with respect to us, which could have a material adverse effect on our business.
  • International expansion of our business exposes us to business, legal, regulatory, political, operational, financial, and economic risks.
  • Our actual or perceived failure to comply with European governmental laws and regulations and other legal obligations related to privacy, data protection and information security could harm our business.
  • If our facilities, or the facilities of our third-party vendors, incur damage or power is lost for a significant length of time, our business will suffer.
  • A significant disruption in our information technology systems or a cybersecurity breach could adversely affect our business.
  • Our existing principal stockholders hold a substantial amount of our common stock and may be able to influence significant corporate decisions, which may conflict with the interest of other stockholders.
  • Our stock price has been, and is likely to continue to be, highly volatile, which could cause the value of an investment in our common stock to decline significantly.
  • Future sales and issuances of securities may dilute the ownership interests of our current stockholders and cause our stock price to decline.
  • We have anti-takeover provisions in our corporate charter documents that may result in outcomes with which you do not agree.
  • We have never paid dividends on our common stock and do not anticipate doing so in the foreseeable future.
  • Natural disasters, epidemic or pandemic disease outbreaks, trade wars, armed conflicts, political unrest or other events could disrupt our business or operations or those of our development partners, manufacturers, regulators or other third parties with whom we conduct business now or in the future.
  • We are subject to legal proceedings, which could harm our reputation or result in other losses or unexpected expenditure of time and resources.
  • Insurance coverage is increasingly more costly and difficult to obtain or maintain.
  • If we fail to retain our existing key personnel or fail to attract and retain additional key personnel, the development of our product candidates, the commercialization of our products, and the related expansion of our business will be delayed or stopped.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accomplished, America, condensed, evidence, fashion, fill, GmbH, hydration, inflation, lifted, move, Pint, pipeline, purpose, signal, subsection, tap, threshold, urine
Removed: accessing, baseline, contemporaneously, Food, hematology, Ireland, map, NaN, nephrology, UK